GeneLink Signs Settlement Agreement with LAB 21
December 3, 2003

Margate, NJ – (Business Wire) – December 3, 2003 – GeneLink BioSciences, Inc. (OTCBB:GNLK).

GeneLink settled the lawsuit it filed against LAB21 in the United States District Court for the District of New Jersey whereby the Court issued a Preliminary Injunction enjoining LAB21 from using any confidential information it learned from GeneLink during a collaborative effort to test market a DNA face cream based on GeneLink’s Proprietary SNP profiling methodology

LAB21 has consented to the entry of a Consent Order that dismisses the action but provides that the current injunction is binding and enforceable against LAB21 for five (5) years, until March 24, 2008. The case was settled for an undisclosed amount.

GeneLink’s CEO, John R. DePhillipo, says “We are very pleased that GeneLink prevailed in this very important case. This settlement protects GeneLink’s Proprietary SNP genetic profiling methodology”.

GeneLink BioSciences, Inc. (www.genelink.info), since 1994, developed the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. With recent breakthroughs, GeneLink is a pioneer and leading provider of DNA tests created to facilitate “genetically guided” health, beauty and wellness products. The company both markets and licenses its proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries. For more information about GeneLink, visit its Web site at www.genelink.info.  For more information on GeneLink’s Dermagenetics™ Assessments, see the article “Designer Cosmetics” in the Business Journal, March 25, 2002 (80(12) p.16-21 or or visit here.

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE: GeneLink BioSciences, Inc.